The Phase III trial of AstraZeneta's new crown vaccine has been suspended for full decryption

(2020/09/11) Takeda Ninlaro multiple myeloma clinical failure $10 billion asset divestiture plan is not completed; (Click on the title, available in the original article) "Pharmaceutical 1st time" Takeda Ninlaro multiple myeloma clinical failure $10 billion divestiture plan not completed September 9, Takeda announced NINLARO™ (ixazomib, Isazzomi™ Specific results of stage 3 clinical studies of TOURMALINE-MM2 in patients with newly diagnosed multiple myeloma (MM) who did not meet the conditions for an introplasty stem cell transplant were used in the treatment of amines and dexamisong (as compared to placebos combined with amines and dexamisong).
test did not reach the statistically significant threshold or the main endpoint of PFS.
nearly two years, Takeda has been paying off its debts by buying Shire for $59 billion, including through the ongoing sale of non-core drugs.
yesterday, Takeda also announced a new deal to sell a number of non-core prescription drugs, mainly in Europe and Canada, to German company Cheplapharm for $562m.
Takeda aims to divest $10 billion in assets, sell businesses that don't match its new positioning over the past two years (five areas of gastrointestinal, rare diseases, oncology, plasma therapy and neuroscience), and make personnel changes to save the company's operating costs.
: The failure of the study clearly clouded the future of the drug.
the 300 million yuan transfer of four pharmaceutical companies no one asked the listed pharmaceutical companies to sell assets into the wind behind the logic is? On September 9th, the shares of four subsidiaries of Laimei Pharmaceuticals were again listed on the Chongqing Stock Exchange for transfer.
this is the 8th transfer of the four subsidiaries by Lemex Pharmaceuticals, the previous seven transfers have not been successful.
's transferred underlying shares are 100% of Hunan Kangyuan Pharmaceutical Co., Ltd., with a transfer base price of 200 million yuan, Sichuan Yanzheng Pharmaceutical Co., Ltd. with a 100% stake and a transfer base price of 110 million yuan, Chongqing Laimei Health Industry Co., Ltd. with a 60% stake with a transfer base price of 0.0001 million yuan, and Chongqing Laiyuan Chinese Medicine tablet Co., Ltd. with a transfer base price of 12.55 million yuan.
headlines: Drug companies "slimming down" is not an exception.
the New Kangjie conventional operation or the market is too aggressive? AstraZeneca's Phase III trial of the new crown vaccine was suspended on September 8 (local time) following news that AstraZeneca had voluntarily suspended a Phase III clinical trial on the new crown vaccine AZD1222 at dozens of clinical trial centres in the United States due to a suspected serious adverse reaction by a participant in a clinical trial in the United Kingdom.
is the world's first suspended phase III clinical trial of the new crown vaccine.
as one of the world's leading candidates in the race for new vaccine research and development, AstraZeneca's move shook capital markets, with U.S. shares trading lower on Sept. 9.
: The market's concern now is how long the test suspension will last.
CPhI Pharmaceuticals Online: The development status and trend of subsulpheric immunoglobulin injection drugs are immunoglobulin-type blood products prepared from a mixture of plasma from thousands of healthy blood donors, the main component of which is immunoglobulin G (IgG).
depending on the injection method, immunoglobulin drugs can be divided into sub-cort injection immunoglobulin (SCIg), intra-intra-intra-intra-intra-intra-intra-intra-intra-intra-intra-intra-immune globulin (IVIg).
: IVIg is beginning to become the preferred treatment for primary immunodeficiency disease.
Pharmaceutical Rubik's Cube Antibody Conjugate (ADC) Pharmacological Dynamics and Bioanalytic ADC (Antibody drug conjugate) is a compound that co-values monoclonal antibodies through a conjugate arm (linker) with small molecule drugs.
ADC drug molecules contain antibodies, linker, small molecule drugs three structural modules.
: Bioanalysis plays a very important role.